MAP2K7 and neoplasm: Sorafenib, a multikinase inhibitor, exerts antineoplastic effects by inhibiting VEGF receptor (VEGFR), platelet‐derived growth factor receptor‐beta (PDGFR‐β), and Raf/MEK/ERK signaling cascades, thereby inhibiting tumor proliferation and angiogenesis [525].